Key result
Urinary angiotensinogen levels were significantly higher in patients with IgA nephropathy than in those with minor glomerular abnormality, and were reduced by valsartan treatment.
Why the study?
Does urinary angiotensinogen reflect intrarenal renin-angiotensin system activity and respond to valsartan in patients with IgA nephropathy?
Population
Patients with IgA nephropathy, patients with minor glomerular abnormality, and healthy volunteers. Excluded…
Comparison
Valsartan 40 mg/day vs Patients with MGA and healthy volunteers…
Design
Cohort
Authors
Loading...
May support urinary angiotensinogen as a biomarker of intrarenal RAS in IgA nephropathy; leaves open its role in guiding ARB therapy.
Cross-Sectional
Does urinary angiotensinogen reflect intrarenal renin-angiotensin system activity and respond to valsartan in patients with IgA nephropathy?
Urinary angiotensinogen serves as a specific, non-invasive biomarker for intrarenal renin-angiotensin system activity in IgA nephropathy and is reduced by ARB therapy.
Nishiyama et al. (2010) conducted a cross-sectional in IgA nephropathy. IgA nephropathy vs. Minor glomerular abnormality (MGA) and healthy volunteers was evaluated on Urinary angiotensinogen levels. Urinary angiotensinogen levels were significantly higher in patients with IgA nephropathy than in those with minor glomerular abnormality, and were reduced by valsartan treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: